25.09.2012 - French pharma company Les Laboratoires Servier beefs up its oncology pipeline with a deal worth up to US$1.2bn.
In its second deal with US-based Macrogenics, the major French pharma company has entered into an option agreement to develop and commercialise three Macrogenics products. Under the terms of the agreement, Macrogenics receives US$20m upfront, as well as US$1.1bn in milestone payments and double digit royalties. It will use its Dual-Affinity Re-Targeting (DART) platform to develop up to three proteins that target un-diagnosed solid and liquid tumours. It retains full development and commercialisation rights to the programmes in the US, Canada, Mexico, Japan, Korea and India, while Servier has the option to obtain an exclusive license covering the rest of the world for each of the programmes.
„We believe bi-specific antibodies are an important new frontier in medicine. Macrogenics is well positioned to be a leader in this exciting area, given the robustness and versatility of their DART platform”, said Stéphane Depil, in charge of Oncology Research & Development at Servier. His company partnered with Macrogenics for the first time in late 2011 on MGA271, a monoclonal antibody that recognises B7-H3, a novel member of the B7 family of immune regulators. With Pfizer and Boehringer Ingelheim, two other major pharma companies are already using the DART platform since at least October 2010.
These deals mark a remarkable comeback for Macrogenics: only two years ago the company spiked ist lead product, type 1 diabetes drug teplizumab, partnered to Eli Lilly & Co., after disappointing Phase III study results.
15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.
12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.
09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.